Venova Medical, Inc.

• 05/09/2024
• Series B
• $30,000,000

Despite clear benefits of initiating hemodialysis with an arteriovenous fistula--including lower mortality, less reinterventions and lower health care costs—few patients in the US do so. Venova Medical is developing the next generation of vascular access systems that will address patient level and system barriers for access creation while simultaneously providing quickly functioning access with less need for reintervention.

---

---